ALS drug study pulled before it even started
NCT ID NCT03474263
First seen May 06, 2026 · Last updated May 06, 2026 · Updated 1 time
Summary
This study was designed to test an experimental drug called IC14 in people with rapidly progressing ALS. Researchers planned to use special brain scans and blood/urine tests to see if the drug could reduce signs of brain inflammation linked to the disease. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Brisbane & Women's Hospital
Herston, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.